Addition of plerixafor to G-CSF in poor mobilizing healthy related donors overcame mobilization failure: An observational case series on behalf of the Grupo Espanol de Trasplante Hematopoyetico (GETH)
Por:
Cid, J, Monsalvo, S, Castillo, C, Pascual, C, Moreno-Jim, G, Lopez-Parra, M, Andon, C, Guerra, L, Esquirol, A, Sanchez-Ortega, I, Ortega, S, Zalba, S, Martinez, C, Rovira, M, Marin, P, Lozano, M
Publicada:
1 abr 2021
Ahead of Print:
1 mar 2021
Resumen:
Plerixafor (Mozobil, Sanofi) is approved for using in patients with lymphoma and multiple myeloma when steady-state mobilization strategies fail. Although off-label use of plerixafor in healthy related donors (HRD) is known, limited data are available and no recommendations exist to guide its use in this setting. With the aim of collecting data from HRDs who received plerixafor in our country, we designed an observational case series study within the Spanish Group of Hematopoietic Transplant and Cell Therapy (GETH). Plerixafor was administered subcutaneously to 30 HRDs at a median dose of 0.24 mg/Kg (interquartile range (IQR): 0.23-0.25) because mobilization failure after using mobilization with G-CSF (mobilization failure was defined as collection of <4.0 ? 106 CD34+ cells/Kg recipient). All HRDs received G-CSF at a median dose of 11 ?g/Kg/day (IQR: 10?12) for 4?5 days. Leukocytapheresis after G-CSF mobilization was performed in 23 (77 %) HRDs collecting a median of 1.6 ? 106 CD34+ cells/Kg recipient weight (IQR: 0.9?2.5). Addition of plerixafor allowed the collection of a higher median number of CD34 cells (4.98 ? 106 CD34+ cells/Kg recipient weight (IQR: 3.5?5.8)) when compared with the collection of CD34+ cells with G-CSF alone (p < 0.01). The final median total number of CD34+ cells collected was 6.1 ? 106/Kg recipient weight (IQR: 4.8?7.3). Mild adverse events related with plerixafor administration were reported in 8 (27 %) donors. In conclusion, addition of plerixafor after G-CSF mobilization failure in HRDs allowed collecting higher number of CD34+ cells in comparison with steady-state mobilization.
Filiaciones:
Cid, J:
UB, Hosp Clin, Dept Hemotherapy & Hemostasis, Apheresis & Cellular Therapy Unit,ICMHO,IDIBAPS, Barcelona, Spain
Monsalvo, S:
Hosp Gregorio Maranon, Madrid, Spain
Castillo, C:
UB, Hosp Clin, Dept Hemotherapy & Hemostasis, Apheresis & Cellular Therapy Unit,ICMHO,IDIBAPS, Barcelona, Spain
Pascual, C:
Hosp Gregorio Maranon, Madrid, Spain
Moreno-Jim, G:
UB, Hosp Clin, Dept Hemotherapy & Hemostasis, Apheresis & Cellular Therapy Unit,ICMHO,IDIBAPS, Barcelona, Spain
Hosp Ramon & Cajal, Madrid, Spain
Lopez-Parra, M:
Hosp Univ Salamanca, Salamanca, Spain
Andon, C:
Complejo Hosp Univ A Coruna, La Coruna, Spain
Guerra, L:
Hosp Univ Gran Canaria Dr Negrin, Las Palmas Gran Canaria, Spain
Esquirol, A:
Hosp Santa Creu & Sant Pau, Barcelona, Spain
Sanchez-Ortega, I:
Hospital Universitario de Gran Canaria Dr. Negrín, Las Palmas de Gran Canaria, Spain
Ortega, S:
Hosp Duran & Reynals, Inst Catala Oncol, Barcelona, Spain
Banc Sang & Teixits, Barcelona, Spain
Zalba, S:
Complejo Hosp Navarra, Pamplona, Spain
Martinez, C:
Hosp Clin Barcelona, Josep Carreras Leukemia Res Fdn, BMT Unit,ICMHO,IDIBAPS, Dept Hematol,UB, Barcelona, Spain
Rovira, M:
Hosp Clin Barcelona, Josep Carreras Leukemia Res Fdn, BMT Unit,ICMHO,IDIBAPS, Dept Hematol,UB, Barcelona, Spain
Marin, P:
Hosp Clin Barcelona, Josep Carreras Leukemia Res Fdn, BMT Unit,ICMHO,IDIBAPS, Dept Hematol,UB, Barcelona, Spain
Lozano, M:
UB, Hosp Clin, Dept Hemotherapy & Hemostasis, Apheresis & Cellular Therapy Unit,ICMHO,IDIBAPS, Barcelona, Spain
|